Extrait

Evaluation of the objective tumor response of the combination therapy with pimasertib plus SAR245409 and of pimasertib plus SAR245409 placebo in subjects with previously treated unresectable low-grade ovarian carcinoma according to Response Evaluation Criteria in Solid Tumors Version 1.1. (RECIST v1.1) as determined by the investigator.

Critère d'inclusion

• Unresectable Low Grade Ovarian Cancer

Liens

• euctr
• euctr
• ictrp
• ictrp
• euctr
• ictrp
• ictrp
• euctr